Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

Haematologica

Volumn 96, Issue 2, 2011, Pages 307-314

  de Lavallade, Hugues ^a   Garland, Paula ^b   Sekine, Takuya ^a   Hoschler, Katja ^b   Marin, David ^a   Stringaris, Kate ^a   Loucaides, Eva ^a   Howe, Katherine ^a   Szydlo, Richard ^a   Kanfer, Ed ^b   Macdonald, Donald ^b   Kelleher, Peter ^b   Cooper, Nichola ^b   Khoder, Ahmad ^a   Gabriel, Ian H ^a   Milojkovic, Dragana ^b   Pavlu, Jiri ^b   Goldman, John M ^a   Apperley, Jane F ^a   Rezvani, Katayoun ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Allogeneic SCT; Cancer; CML; Efficacy; H1N1 vaccine; Hematologic malignancies; Hematology; Immunocompromised host; Influenza; Leukemia; Lymphoma

Indexed keywords

INFLUENZA VACCINE; RITUXIMAB;

ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG REEXPOSURE; ECCHYMOSIS; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PAIN; SEASONAL INFLUENZA; SEROCONVERSION; SKIN INDURATION; SKIN REDNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; VACCINATION; YOUNG ADULT;

EID: 79551676184     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.032664     Document Type: Article

References (34)

1. The European Agency for the Evaluation of Medicinal Products (EMEA). European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1)2009. http://www.ema.europa.eu/docs/en_GB/document_library/Press_releas e/2009/12/WC500018421.pdf
2. Department of Health. H1N1 swine flu vaccination programme 2009-2010.
3. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010;28(14):2481-90.
4. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100-8.
5. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf. 1-3-1997.
6. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504.
7. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008;42(10):637-41.
8. Ring A, Marx G, Steer C, Harper P. Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer. 2002;10(6):462-5.
9. Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Parind P, et al. Humoral and cellular immunity to primary H1N1 infection in patients with hematological malignancies and following stem cell transplantation. Biol Blood Marrow Transplant. 2010 Aug 10. [Epub ahead of print]
10. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59- adjuvanted vaccine. N Engl J Med. 2009; 361(25):2424-35.
11. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009; 361(25):2405-13.
12. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2010; 375(9708):56-66.
13. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010; 375(9708):41- 8.
14. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005; 130(1):96-8.
15. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006; 176(10):6333-9.
16. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine. 2010;28(38):6145-51.
17. Smithson WA, Siem RA, Ritts RE Jr, Gilchrist GS, Burgert EO Jr, Ilstrup DM, et al. Response to influenza virus vaccine in children receiving chemotherapy for malignancy. J Pediatr. 1978;93(4):632-4.
18. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis. 1993; 12(10):778-82.
19. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90(6):2188-95.
20. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257-9.
21. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-33.
22. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop. 2009;49(1):9-13.
23. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol. 2009;37(12):1435-44.
24. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood. 2006; 108(10):3406-13.
25. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105(6):2473-9.
26. Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABLtumors. J Immunol. 2008;181(10):6955-63.
27. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945-52.
28. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA. 2009; 106(48):20365-70.
29. Ge X, Tan V, Bollyky PL, Standifer NE, James EA, Kwok WW. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swineorigin influenza A virus. J Virol. 2010;84(7): 3312-9.
30. He XS, Holmes TH, Sasaki S, Jaimes MC, Kemble GW, Dekker CL, et al. Baseline levels of influenza-specific CD4 memory Tcells affect T-cell responses to influenza vaccines. PLoS One 2008;3(7):e2574.
31. Keynan Y, Card CM, Ball BT, Li Y, Plummer FA, Fowke KR. Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains. Clin Microbiol Infect. 2010;16(8):1179-86.
32. McElhaney JE, Hooton JW, Hooton N, Bleackley RC. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine. 2005;23(25):3294-300.
33. Wang RX, Boland GJ, van HJ, de Gast GC. Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol. 2004; 10(2):260-3.
34. World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. http://www.who.int/csr/disease/ influenza/201002_Recommendation.pdf.20 10.